Article

Three-month Antibody Persistence of a Bivalent Omicron-containing Booster Vaccine Against COVID-19

2022-11-09

Abstract excerpt

<title>Abstract</title> <p>We previously presented day 29 interim safety and immunogenicity results from a phase 2/3 study comparing the Omicron-BA.1-containing bivalent vaccine mRNA-1273.214 (50-µg) to the 50-µg mRNA-1273 booster in adults who previously received the mRNA-1273 primary series (100-µg) and mRNA-1273 first booster (50-µg) dose. Here we present day 91 post-booster results. Participants were sequenti...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d5ce9ed3-1583-5a21-bd31-5884bf779248
DOI: 10.21203/rs.3.rs-2239682/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Three-month Antibody Persistence of a Bivalent Omicron-containing Booster Vaccine Against COVID-19DOI 10.21203/rs.3.rs-2239682/v1Read

A Bivalent Omicron-containing Booster Vaccine Against Covid-19Semantic proximity Read

Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19Semantic proximity Read

Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster VaccineSemantic proximity Read

Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim resultsSemantic proximity Read

Interim Safety and Immunogenicity of COVID-19 Omicron-BA.1 Variant-Containing Vaccine in ChildrenSemantic proximity Read

Reactogenicity, Safety, and Serological and Cellular Immunogenicity of a Booster Dose of SARS-CoV-2 mRNA Prototype, Variant, and Bivalent VaccinesSemantic proximity Read

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19Semantic proximity Read

Evaluation of bivalent Omicron BA.1 booster vaccination after different priming regimens in healthcare workers (SWITCH ON): a randomized controlled trialSemantic proximity Read

Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine doseSemantic proximity Read

Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variantSemantic proximity Read

Immunogenicity and Safety of COVID-19 Booster Vaccination: A Real-World Clinical Trial to Identify the Best Vaccination StratagySemantic proximity Read

Neutralizing Activities against the Omicron Variant after a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac VaccinationSemantic proximity Read